For patients diagnosed with Amyotrophic Lateral Sclerosis (ALS), the clinical heterogeneity of disease presentation and progression continues to confound the identification of robust outcome measures and biomarkers that can be used as surrogates of progression to provide faster and improved decision-making during clinical trials. To overcome this limitation we developed a non-invasive imaging strategy, termed MRI Cytography (MRC) that is uniquely sensitive to abnormal muscle cytoarchitecture. In a preclinical model of ALS, MRC was able to reliably differentiate between normal and degenerated muscle microstructure.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords